ArticleNature2023
A small-molecule PI3Kα activator for cardioprotection and neuroregeneration.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
24.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 138 citations in OpenAlex.
- Stemness in Colon Cancer.Methods in molecular biology (Clifton, N.J.) · 2027Article
- PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12.Nature communications · 2026Article
- PI(3,5)PScience advances · 2026Article
- Molecular architecture responsible for specific inhibition of oncogenic PI3KActa pharmaceutica Sinica. B · 2026Article
- PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.Cancer research · 2026Article
- Endophytic Aspergillus glaucus as a novel epothilone B producer: Antiproliferative activity and in silico analysis.Applied microbiology and biotechnology · 2026Article
- Context-dependent selection sculpts mutational landscapes in the normal lung.Research square · 2026Article
- Clinical spectrum of extreme insulin resistance syndromes treated with rhIGF-1: A single-center experience.The Journal of clinical endocrinology and metabolism · 2026Observational
- A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026Review
- Leonurine-StandardizedJournal of microbiology and biotechnology · 2026Article
- Peptides Targeting GDNF Family Receptor Alpha 1 (GFRα1) Mimic Glial Cell Line-Derived Neurotrophic Factor (GDNF) Bioactivity.Journal of medicinal chemistry · 2026Article
- 5,7-Dimethoxyflavone Attenuates Obesity-Associated Muscle Atrophy via AMPK and PI3K/Akt Pathways inJournal of microbiology and biotechnology · 2026Article
- The proximal lipid phase of PI3K signaling is confined to the plasma membrane.bioRxiv : the preprint server for biology · 2026Article
- Injectable alginate composite hydrogel with spatiotemporal codelivery of pro-angiogenic and anti-fibrotic agents for synergistic myocardial repair.Materials today. Bio · 2026Article
- Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling.Physiological reports · 2026Article
- Effect of lumbrokinase on a rat model of hyperlipidemia-induced erectile dysfunction.Translational andrology and urology · 2026Article
- Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia-Reperfusion Injury.Cardiovascular drugs and therapy · 2026Article
- Activating protein kinases to treat diseases: Current understanding and future challenges.Acta pharmaceutica Sinica. B · 2026Review
- Molecular and Cellular Mechanisms of Myocardial Ischemia and Reperfusion Injury: A Narrative Review.Cells · 2026Review
- Protection against myocardial ischemia reperfusion injury by liquiritin: involvement of autophagy restoration targeting PIK3CA.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
41 authors at 11 institutions in 2 countries.
Grace Q GongCell Signalling, Cancer Institute, University College London, London, UK.ORCID 0000-0002-7609-0466
Benoit BilangesCell Signalling, Cancer Institute, University College London, London, UK.ORCID 0000-0003-4400-3716
Ben AllsopDrug Discovery Group, Translational Research Office, University College London, London, UK.
Glenn R MassonMedical Research Council Laboratory of Molecular Biology, Cambridge, UK.ORCID 0000-0002-1386-4719
Victoria RobertonUCL Centre for Nerve Engineering, UCL School of Pharmacy, University College London, London, UK.ORCID 0000-0002-0404-6984
Trevor AskwithDrug Discovery Group, Translational Research Office, University College London, London, UK.
Sally OxenfordDrug Discovery Group, Translational Research Office, University College London, London, UK.
Ralitsa R MadsenCell Signalling, Cancer Institute, University College London, London, UK.
Sarah E ConduitCell Signalling, Cancer Institute, University College London, London, UK.ORCID 0000-0002-5075-8851
Dom BelliniMedical Research Council Laboratory of Molecular Biology, Cambridge, UK.
Martina FitzekHit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, Macclesfield, UK.
Matt CollierHit Discovery, Discovery Sciences, R&D, AstraZeneca, Alderley Park, Macclesfield, UK.
Osman NajamThe Hatter Cardiovascular Institute, University College London, London, UK.
Zhenhe HeThe Hatter Cardiovascular Institute, University College London, London, UK.
Ben WahabMedicines Discovery Institute, School of Biosciences, Cardiff University, Cardiff, UK.
Stephen H McLaughlinMedical Research Council Laboratory of Molecular Biology, Cambridge, UK.ORCID 0000-0001-9135-6253
A W Edith ChanWolfson Institute for Biomedical Research, University College London, London, UK.
Isabella FeierbergMolecular AI, Discovery Sciences, R&D, AstraZeneca, Waltham, MA, USA.
Andrew MadinHit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
Daniele MorelliCell Signalling, Cancer Institute, University College London, London, UK.
Amandeep BhamraProteomics Research Translational Technology Platform, Cancer Institute, University College London, London, UK.
Vanesa VinciauskaiteDivision of Cellular Medicine, School of Medicine, University of Dundee, Dundee, UK.ORCID 0000-0001-9226-1731
Karen E AndersonSignalling Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0002-7394-6660
Silvia SurinovaProteomics Research Translational Technology Platform, Cancer Institute, University College London, London, UK.ORCID 0000-0003-0442-9595
Nikos PinotsisInstitute of Structural and Molecular Biology, Birkbeck College, London, UK.ORCID 0000-0002-5096-257X
Elena Lopez-GuadamillasCell Signalling, Cancer Institute, University College London, London, UK.
Matthew WilcoxUCL Centre for Nerve Engineering, UCL School of Pharmacy, University College London, London, UK.
Alice HooperDrug Discovery Group, Translational Research Office, University College London, London, UK.
Chandni PatelDrug Discovery Group, Translational Research Office, University College London, London, UK.
Maria A WhiteheadCell Signalling, Cancer Institute, University College London, London, UK.
Tom D BunneyInstitute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK.ORCID 0000-0002-0281-8813
Len R StephensSignalling Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0002-2771-3487
Phillip T HawkinsSignalling Programme, Babraham Institute, Cambridge, UK.ORCID 0000-0002-6979-0464
Matilda KatanInstitute of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK.ORCID 0000-0001-9992-8375
Derek M YellonThe Hatter Cardiovascular Institute, University College London, London, UK.
Sean M DavidsonThe Hatter Cardiovascular Institute, University College London, London, UK.ORCID 0000-0001-5182-4980
David M SmithEmerging Innovations, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0001-6831-280X
James B PhillipsUCL Centre for Nerve Engineering, UCL School of Pharmacy, University College London, London, UK.ORCID 0000-0001-8117-3074
Richard AngellDrug Discovery Group, Translational Research Office, University College London, London, UK.
Roger L WilliamsMedical Research Council Laboratory of Molecular Biology, Cambridge, UK.ORCID 0000-0001-7754-4207
Bart VanhaesebroeckCell Signalling, Cancer Institute, University College London, London, UK. bart.vanh@ucl.ac.uk.ORCID 0000-0002-7074-3673
University College London · GBAstraZeneca (United Kingdom) · GBMRC Laboratory of Molecular Biology · GBBabraham Institute · GBInstitute of Structural and Molecular Biology · GBNerve Centre · GBAstraZeneca (United States) · USCancer Research UK · GBCardiff University · GBUniversity of Dundee · GBWolfson Foundation · GB
Funding
Biotechnology and Biological Sciences Research Council BBS/E/B/000C0415Cancer Research UK 25722Cancer Research UK A20265Medical Research Council MC_PC_15063Medical Research Council MC_PC_16063Medical Research Council MC_PC_16087Medical Research Council MC_PC_17202Medical Research Council MC_PC_18063Medical Research Council MC_U105184308Medical Research Council MC_UP_1201/6Wellcome Trust 220464
Abstract
Harnessing the potential beneficial effects of kinase signalling through the generation of direct kinase activators remains an underexplored area of drug development
Indexed as
Nerve RegenerationAnimalsBiocatalysisCardiotonic AgentsCell ProliferationClass I Phosphatidylinositol 3-KinasesHumansNeoplasmsNerve CrushNeuritesProtein ConformationProtein IsoformsReperfusion InjurySignal TransductionCardiotonic AgentsClass I Phosphatidylinositol 3-KinasesPIK3CA protein, humanProtein Isoforms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.